Oophoritis Treatment Market Size, Share, Growth, Forecast 2030

Oophoritis Treatment Market

Oophoritis Treatment Market By Symptoms (Pain in Lower Abdomen & Pelvis, Heavier Menstrual Bleeding, Pain During Intercourse, Heavy Vaginal Discharge, Burning Sensations, Difficulty Urinating, and Others), By Diagnosis (Blood & Urine Tests, Pelvic Exam, Pelvic Ultrasound, Laparoscopy, and Others), By Treatment (Medications, Hormone Replacement Therapy, Surgery, and Others), By Route of Administration (Oral, Parenteral, and Others), By End User (Hospitals, Specialty Clinics, Homecare, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2023 – 2030

Category: Healthcare Report Format : PDF Pages: 208 Report Code: ZMR-7423 Published Date: Aug-2023 Status : Published
Market Size in 2022 Market Forecast in 2030 CAGR (in %) Base Year
USD 501 million USD 768 million 5.5% 2022

Oophoritis Treatment Industry Prospective:

The global Oophoritis Treatment market size was worth around USD 501 million in 2022 and is predicted to grow to around USD 768 million by 2030 with a compound annual growth rate (CAGR) of roughly 5.5% between 2023 and 2030.

Global Oophoritis Treatment Market SizeRequest Free Sample

The report analyzes the global Oophoritis Treatment market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the oophoritis treatment industry.       

Oophoritis Treatment Market: Overview

Oophoritis is defined as an inflammation of the ovarian tissue in one or both ovaries, which causes the ovaries to expand and exhibit cysts. Oocytes are found in the ovaries. Oophoritis is frequently considered to be a symptom of pelvic inflammatory disease (PID). Oophoritis may sometimes be accompanied by a fallopian tube infection. When this occurs, the illness is known as salpingo oophoritis. The most frequent word used to refer to oophoritis is salpingo oophoritis or PID. Oophoritis is frequently observed associated with fallopian tube inflammation and is frequently seen along with PID.

Key Insights

  • As per the analysis shared by our research analyst, the global Oophoritis Treatment market is estimated to grow annually at a CAGR of around 5.5% over the forecast period (2023-2030).
  • In terms of revenue, the global Oophoritis Treatment market size was valued at around USD 501 million in 2022 and is projected to reach USD 768 million, by 2030.
  • The global Oophoritis Treatment market is being driven by the increasing prevalence of Pelvic Inflammatory Disease (PID).
  • Based on the symptoms, the pain in the lower abdomen and pelvis segment is expected to hold a significant market share over the forecast period.
  • Based on the diagnosis, urine tests are expected to dominate the market during the forecast period.
  • Based on the route of administration, the oral segment is expected to dominate the market during the forecast period.
  • Based on region, North America is expected to dominate the market over the forecast period.

Oophoritis Treatment Market SizeRequest Free Sample

Oophoritis Treatment Market: Growth Drivers

The growing prevalence of Pelvic Inflammatory Disease (PID) drives the market growth

The growing prevalence of Pelvic Inflammatory Disease (PID) is expected to drive the global oophoritis treatment market growth over the forecast period. Acute and subclinical infections of the uterus, fallopian tubes, and ovaries in females are referred to as pelvic inflammatory disease (PID). Frequently, these infections also affect the other pelvic organs. It causes tubo-ovarian abscess, endometritis, salpingitis, oophoritis, peritonitis, and/or perihepatitis. According to secondary analysis, in the span of their lives, around 1 in 7 women will have PID treatment. Each year, this illness affects about a million women. PID affects 1% of women between the ages of 15 and 25 yearly. PID is a significant source of morbidity, leading to more than 1 million clinic visits annually and 342,000 emergency department visits, more than 100,000 surgical operations are carried out each year for a diagnosis of PID, and almost 200,000 women need to be hospitalized. Therefore, the aforementioned facts support the market growth during the forecast period.

Oophoritis Treatment Market: Restraints

High cost of treatment and regulatory challenges hamper the market growth

It might be expensive to use advanced treatment options or therapies that need specific drugs or procedures. Patients seeking proper care may be constrained by high treatment expenses, particularly in areas with limited access to healthcare resources. Additionally, the complicated and expensive licensing procedure for novel medications may discourage pharmaceutical firms from funding oophoritis-specific therapy. Thus, this is expected to act as a major restraint to the oophoritis treatment industry growth over the forecast period.

Oophoritis Treatment Market: Opportunities

Increasing research and development offers a lucrative opportunity for the market growth

There is an opportunity that more specialized and efficient therapies for oophoritis will be created as a result of developments in medical research and technology. Personalized treatments based on the precise underlying cause of the ailment are also included, as are unique therapeutic approaches, precision medicine, and new treatment alternatives. Therefore, the growing research and development in the area of these conditions is expected to provide enormous opportunities for oophoritis treatment market growth during the forecast period.

Oophoritis Treatment Market: Challenges

Lack of awareness and specific therapies act as a major challenge to the market growth

Since oophoritis is a very uncommon ailment, it's possible that many individuals, even medical professionals, are unaware of its signs and possible treatments. Lack of knowledge may cause a delayed diagnosis and improper or insufficient therapy. In addition, there may be a need for certain treatments depending on the underlying reasons for the oophoritis. It could be difficult to adequately treat the ailment if there are few therapy alternatives available. Thus, this is expected to act as a major challenge to the market growth over the forecast period.

Oophoritis Treatment Market: Segmentation

The global Oophoritis Treatment industry is segmented based on symptoms, diagnosis, treatment, route of administration, end-user, distribution channel, and region.

Based on the symptoms, the global market is bifurcated into pain in the lower abdomen & pelvis, heavier menstrual bleeding, pain during intercourse, heavy vaginal discharge, burning sensations, difficulty urinating, and others. The pain in the lower abdomen and pelvis segment is expected to hold a significant market share over the forecast period. Oophoritis frequently causes pain in the lower abdomen and pelvis, which can considerably reduce a patient's quality of life. The desire for drugs or treatments that focus on pain management among people with oophoritis may be driven by the need for efficient pain alleviation. Thereby, driving the segment growth.

Based on the diagnosis, the oophoritis treatment market is segmented into blood and urine tests, pelvic exams, pelvic ultrasounds, laparoscopy, and others. Urine tests are expected to dominate the market during the forecast period. Genitourinary infections that may be causing Oophoritis can be identified with the aid of urine tests like urinalysis and urine culture. The presence of bacteria or other pathogens in the urinary tract that may have reached the ovaries and triggered inflammation can be found using these tests. Additionally, testing on the urine can assist distinguish between various forms of oophoritis. For instance, if a urine culture identifies the particular bacteria causing the infection, it can help choose the best antibiotic to use for therapy.

Based on the treatment, the global oophoritis treatment industry is divided into medications, hormone replacement therapy, surgery, and others.

Based on the route of administration, the market is bifurcated into oral, parenteral, and others. The oral segment is expected to dominate the market during the forecast period owing to its benefits. Oral medications are often more convenient for patients since they can be self-administered and do not require specialized medical procedures. Thus, this is expected to drive segment expansion over the forecast period.

Based on the end user, the oophoritis treatment industry is divided into hospitals, specialty clinics, homecare, and others.

Based on the distribution channel, the global oophoritis market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.

Oophoritis Treatment Market: Report Scope

Report Attributes Report Details
Report Name Oophoritis Treatment Market Report
Market Size in 2022 USD 501 Million
Market Forecast in 2030 USD 768 Million
Growth Rate CAGR of 5.5%
Number of Pages 208
Key Companies Covered Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Abbott, F. Hoffmann-La Roche Ltd., Pfizer Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Johnson & Johnson Private Limited, Novartis AG, Boehringer Ingelheim International GmbH, Bayer AG, Lupin, Aurobindo Pharma, Eli Lilly and Company, AstraZeneca, Merck & Co. Inc., Allergan, Sun Pharmaceutical Industries Ltd. and Sumitomo Corporation, among others..
Segments Covered By Symptoms, By Diagnosis, By Treatment, By Route of Administration, By End User, By Distribution Channel, and By Region
Regions Covered North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)
Base Year 2022
Historical Year 2017 to 2021
Forecast Year 2023 - 2030
Customization Scope Avail customized purchase options to meet your exact research needs. Request For Customization

Oophoritis Treatment Market: Regional Analysis

North America is expected to dominate the market over the forecast period

North America is expected to dominate the global oophoritis treatment market over the forecast period. The growth in the region is attributable to the developed healthcare infrastructure and high research and development funding. For instance, according to the National Health Expenditure Account (NHEA), spending on health care in the United States increased by 2.7 percent in 2021 to $4.3 trillion, or $12,914 per person.  Spending on healthcare accounted for 18.3 percent of the country's GDP.

Global Oophoritis Treatment Market SizeRequest Free Sample

Additionally, in 2020, the National Science Foundation's National Center for Science and Engineering Statistics (NCSES) estimates that the value of research and experimental development (R&D) carried out in the United States was $717.0 billion. Based on performer-reported expectations, the projected total for 2021 is $791.9 billion. Moreover, the growing prevalence of PID is expected to drive market growth. Furthermore, the presence of major pharmaceutical players is one of the significant drivers that propel the market growth in the region.

Oophoritis Treatment Market: Competitive Analysis

The global Oophoritis Treatment market is dominated by players like:

  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Private Limited
  • Novartis AG
  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • Lupin
  • Aurobindo Pharma
  • Eli Lilly and Company
  • AstraZeneca
  • Merck & Co. Inc.
  • Allergan
  • Sun Pharmaceutical Industries Ltd.
  • Sumitomo Corporation

The global Oophoritis Treatment market is segmented as follows:

By Symptoms

  • Pain in Lower Abdomen and Pelvis
  • Heavier Menstrual Bleeding
  • Pain During Intercourse
  • Heavy Vaginal Discharge
  • Burning Sensations
  • Difficulty Urinating
  • Others

By Diagnosis

  • Blood and Urine Tests
  • Pelvic Exam
  • Pelvic Ultrasound
  • Laparoscopy
  • Others

By Treatment

  • Medications
  • Hormone Replacement Therapy
  • Surgery
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By End User

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

FrequentlyAsked Questions

Oophoritis is defined as an inflammation of the ovarian tissue in one or both ovaries, which causes the ovaries to expand and exhibit cysts. Oocytes are found in the ovaries. Oophoritis is frequently considered to be a symptom of pelvic inflammatory disease (PID). Oophoritis may sometimes be accompanied by a fallopian tube infection.

The growing prevalence of Pelvic Inflammatory Disease (PID) is expected to drive the market growth over the forecast period. Acute and subclinical infections of the uterus, fallopian tubes, and ovaries in females are referred to as pelvic inflammatory disease (PID). Frequently, these infections also affect the other pelvic organs.

According to the report, the global oophoritis treatment market size was worth around USD 501 million in 2022 and is predicted to grow to around USD 768 million by 2030.

The global Oophoritis Treatment market is expected to grow at a CAGR of 5.5% during the forecast period.

The global Oophoritis Treatment market growth is expected to be driven by North America. It is currently the world’s highest revenue-generating market due to the growing prevalence of PID and rising investment in R&D.

The global Oophoritis Treatment market is dominated by players like Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Abbott, F. Hoffmann-La Roche Ltd., Pfizer Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Johnson & Johnson Private Limited, Novartis AG, Boehringer Ingelheim International GmbH, Bayer AG, Lupin, Aurobindo Pharma, Eli Lilly and Company, AstraZeneca, Merck & Co., Inc., Allergan, Sun Pharmaceutical Industries Ltd. and Sumitomo Corporation, among others.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed